Abstract β-thalassemia is a hereditary hematological disease caused by over 350 mutations
in the β-globin gene (HBB). Identifying the genetic variants affecting fetal hemoglobin (HbF) …

Abstract Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the
frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated …

The primary β-globin gene mutation that causes sickle cell disease (SCD) has significant
pathophysiological consequences that result in hemolytic events and the induction of the …

The β-thalassemias are a group of hereditary hematological diseases caused by over 300
mutations of the adult β-globin gene. Together with sickle cell anemia, thalassemia …

Sickle cell disease (SCD) had first been mentioned in the literature a century ago.
Advancement in the molecular basis of the pathophysiology of the disease opens the door …

Sodium butyrate (NaB), a histone deacetylase (HDAC) inhibitors, has been reported to
attenuate hyperglycemia in rats. Our objective was to explore the effect and underlying …

Thalassemia are a group of inherited blood disorders caused by the decrease or absence of
beta-globin chain synthesis will be determined with decrease in erythrocyte hemoglobin …

Sickle cell disease (SCD) is an autosomal recessive blood disorder which occurs due to
point mutation in the β-globin chain of hemoglobin. Since the past decades, various …

Background The major therapeutic benefit of hydroxyurea, the only FDA-approved
pharmacologic treatment for sickle cell disease (SCD), is directly related to fetal hemoglobin …

Today the regulatory role of microRNAs (miRs) is well characterized in many diverse cel-
lular processes. MiR-based regulation is categorized under epigenetic regulatory mecha …